Efficacy of a novel multi component TCM therapy in AD patients

TCM offers interesting novel treatment options for Atopic Dermatitis (AD). In the present open-label clinical trial, the efficacy and safety of the multi component therapy approach Kujin-Plus was inves- tigated. 94 AD patients received the formula Kujin-Plus-I orally, combined with both the skin lotion Kujin-Plus-II, and the ointment Kujin-Plus-III. All raw drugs were extracted with boiling wa- ter for 5h, concentrated and reworked into the formulations. Standardized scores were used for evaluating the severity of the disease (clinical score; 0–4) and the severity of pruritus (pruritus score; 0–4) with both scores having significantly improved at the end of treatment (P<0.01; nonparametric test) after 12 months. Blood eosinophil-ratio and serum IgE-levels, elevated in AD patients, were significantly reduced at the end of therapy (P<0.001). Of 94 AD patients, 32 were markedly im- proved, 59 were improved, 3 were slightly improved with no case of ineffective treatment. There was no hint of renal or hepatic toxicity or other adverse effects. Thus, the present study confirms that Kujin-Plus therapy is clinically efficacious on otherwise intractable AD, accomplishing a significant reduction in blood eosinophil-ratio and serum IgE-level.